Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Duelmen – page 103

1 729 clinical trials in Duelmen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Duelmen at a glance
1 729
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 729 trials in Duelmen

Open in trial search

Sepsis+1

Not recruiting

Study on Epirubicin and Sodium Chloride for Patients with Sepsis or Septic Shock in Intensive Care Units

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Breast cancer

Not recruiting

Study on Trastuzumab Deruxtecan and Drug Combination for Patients with High-Risk HER2-Positive Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB

Study on Long-Term Safety and Efficacy of Cebsulfase Alfa for Children with Late Metachromatic Leukodystrophy Receiving Intrathecal Enzyme Replacement

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Cebsulfase Alfa
  • Sponsor:Shire Human Genetic Therapies Inc.

Leukaemia+1

Not recruiting

Study on the Safety of ATreg Cells for Patients with Leukemia After Stem Cell Transplant to Reduce Graft vs Host Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Cd4+ And Cd25+ T Lymphocytes Ex Vivo Incubated With Gp120
  • Sponsor:ActiTrexx GmbH

Study on the Effect of Extending Imatinib Treatment from Three to Five Years for Patients with High-Risk Gastrointestinal Stromal Tumor (GIST)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Region Skane

Study on the Effects of Vidofludimus Calcium in Adults with Relapsing Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Vidofludimus Calcium
  • Sponsor:Immunic AG

Study on the Safety and Effects of Lutetium (177Lu) Vipivotide Tetraxetan in Adults with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Novartis Pharma AG

Malignant glioma

Not recruiting

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:Day One Biopharmaceuticals Inc.

Acoustic neuroma

Not recruiting

Study on Nimodipine for Hearing Preservation in Patients Undergoing Acoustic Schwannoma Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nimodipine
  • Sponsor:Martin-Luther-Universitaet Halle-Wittenberg

Insomnia

Not recruiting

Study to Determine Safe and Effective Dose of Daridorexant for Treating Insomnia in Children and Adolescents Aged 10 to 18 Years

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Daridorexant
  • Sponsor:Idorsia Pharmaceuticals Ltd.

Study Comparing Tacrolimus Formulations for Preventing Liver Transplant Rejection in New Adult Recipients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Universitaetsklinikum Regensburg AöR

Study of Bemarituzumab with Irinotecan, Paclitaxel, Ramucirumab, or Trifluridine/Tipiracil for Advanced Stomach or Gastroesophageal Cancer in Patients After Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Duelmen

What the registry says about research in the country

01 Immune System Diseases

In Dülmen, several recruiting studies focus on immune system diseases, especially psoriasis and chronic spontaneous urticaria. The research is aimed at finding better ways to control symptoms, assess treatment benefit, and support longer-term disease management.

  • Moderate to severe plaque psoriasis
  • Mild to moderate psoriasis
  • Chronic spontaneous urticaria
  • Evaluating treatment effectiveness and safety

These trials include studies of new therapies and comparisons with established options to improve care for people living with persistent inflammatory skin conditions.

02 Skin and Connective Tissue Diseases

Research in skin and connective tissue diseases is a major part of the local clinical trial landscape, with studies covering atopic dermatitis, acne, and different forms of psoriasis. The overall goal is to test new topical and oral treatments that may offer better symptom relief and disease control.

  • Mild to moderate atopic dermatitis
  • Papulopustular acne
  • Chronic stable plaque psoriasis
  • Comparing new treatments with approved therapies or vehicle

These studies help researchers understand how well candidate treatments reduce skin inflammation, improve visible lesions, and support longer-lasting control of chronic skin disease.

03 Parasitic Diseases

Clinical research also includes parasitic diseases, with scabies being a key focus. The studies are designed to evaluate how well standard therapies work in clearing infection and restoring skin health.

  • Scabies
  • Assessing clinical response after treatment
  • Evaluating symptom resolution and treatment success

This area reflects practical, patient-centered research aimed at confirming effective care for a common contagious skin condition.

04 Topical Treatment Development

A number of trials in the city are centered on topical medicines for inflammatory skin disorders, including gels and ointments for acne, atopic dermatitis, and psoriasis. The focus is on comparing candidate products with approved treatments and non-active controls.

  • Testing new gels and ointments
  • Comparing against reference treatments
  • Improving local symptom control

These studies aim to refine everyday treatment options that may be easier to use and more effective for patients with chronic skin conditions.

05 Long-Term Disease Control

Some research is directed at long-term disease control, looking at how well treatments maintain benefit over time in chronic conditions such as psoriasis and urticaria. This helps determine whether a therapy can keep symptoms from returning or worsening.

  • Tracking time to disease worsening
  • Monitoring treatment durability
  • Supporting chronic disease management

Such studies are especially valuable for people who need sustained relief rather than short-term improvement alone.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.